JPMorgan Chase & Co. Raises Smith & Nephew (LON:SN) Price Target to GBX 1,381

Smith & Nephew (LON:SN) had its target price lifted by JPMorgan Chase & Co. from GBX 1,300 ($16.33) to GBX 1,381 ($17.35) in a research note released on Thursday, Marketbeat Ratings reports. They currently have an overweight rating on the stock.

SN has been the topic of several other reports. Barclays reissued an equal weight rating and issued a GBX 1,150 ($14.45) price objective on shares of Smith & Nephew in a research report on Friday, February 9th. Berenberg Bank reiterated a buy rating and issued a GBX 1,450 ($18.21) target price on shares of Smith & Nephew in a research note on Thursday. Finally, Royal Bank of Canada reissued an outperform rating and set a GBX 1,500 ($18.84) price target on shares of Smith & Nephew in a research report on Friday, April 5th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of GBX 1,346.20 ($16.91).

Smith & Nephew Stock Performance

Shares of SN stock opened at GBX 996.80 ($12.52) on Thursday. The company has a current ratio of 1.77, a quick ratio of 0.84 and a debt-to-equity ratio of 59.11. The company has a market cap of £8.72 billion, a PE ratio of 4,153.33, a P/E/G ratio of 0.46 and a beta of 0.51. The company’s fifty day simple moving average is GBX 1,018.36 and its 200-day simple moving average is GBX 1,035.12. Smith & Nephew has a 52 week low of GBX 887 ($11.14) and a 52 week high of GBX 1,316.75 ($16.54).

Smith & Nephew Increases Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Thursday, March 28th will be paid a dividend of $0.23 per share. The ex-dividend date is Thursday, March 28th. This is an increase from Smith & Nephew’s previous dividend of $0.14. This represents a dividend yield of 1.62%. Smith & Nephew’s dividend payout ratio (DPR) is currently 12,500.00%.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.